Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enalapril + lercanidipine
- Development stage
- Discontinued
- Lead developer
- KRKA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Enalapril + lercanidipine** is an oral fixed-dose antihypertensive combination of enalapril, an angiotensin-converting enzyme inhibitor prodrug, and lercanidipine, a dihydropyridine calcium-channel blocker. Enalapril is converted to enalaprilat and reduces angiotensin II formation, while lercanidipine inhibits L-type calcium-channel-mediated vascular smooth-muscle contraction; together these complementary actions lower peripheral vascular resistance and blood pressure. The combination was developed by Recordati and is marketed in multiple countries for essential hypertension, generally when blood pressure is insufficiently controlled with enalapril alone. ([recordati.com](https://recordati.com/wp-content/uploads/2023/06/slides-32-1-1.pdf))
- Brand names
- AtoverCarmen ACECoriprenElernapElyrnoEnacanpinLecorin ACELercanil ACELercapin ACELercaprelLercapressLercarilLerpinLertecTansiprexVasodip ComboZanicomboZanidualZanerilZanextraZanipressZaniprilZanitek
- Other names
- enalapril + lercanidipineenalapril maleate + lercanidipine hydrochlorideenalapril maleate / lercanidipineenalapril/lercanidipinelercanidipine + enalapril
02
Targets
ACE (Angiotensin Converting Enzyme)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on enalapril + lercanidipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enalapril + lercanidipine.